Universal Technical Institute, Inc. (UTI), a workforce-solutions provider of transportation, skilled-trades, and healthcare education programs, carries a "Strong Buy" consensus from the six analysts tracked by S&P Global. Their price targets produce an average of $38.33, which rounds to the $38 central target used here, with a low around $30 and a high around $45.
Individual views differ meaningfully. Lake Street's Eric Martinuzzi reiterated a Buy with a $37 target in early October, while B. Riley maintained a Buy near $45. On the cautious side, Texas Capital Securities downgraded the stock to Hold in late September, cutting its target sharply to $25. Because several targets predate the company's most recent guidance update, there is risk that the range shifts lower as analysts revisit their models. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
UTI closed near $22.04, giving it a market capitalization of roughly $1.2 billion and a trailing P/E (price-to-earnings) ratio in the mid-30s. From that level, reaching $38 implies upside of about 72% — a very large move by any standard. The stock has been volatile: it traded as high as about $51 in mid-2026 before retreating toward a 52-week low near $18 in late September.
The latest quarter underscores the challenge. Fiscal fourth-quarter adjusted EPS (earnings per share) of $0.32 missed the $0.52 consensus, and the company guided fiscal 2027 EPS to a midpoint of just $0.05, well below the prior year's $0.60 and analyst expectations. Revenue, by contrast, grew 6% and 2027 revenue guidance came in above estimates, showing the business is still expanding even as profitability is being reinvested into growth.
The bull case rests on durable demand. Full-year revenue rose 7.4% to $897 million, average full-time active students increased 6.6%, and new student starts climbed 7%. Management is pursuing a "North Star" strategy that includes up to 12 new campus openings and roughly 45 new programs through fiscal 2029, targeting capacity for more than 10,000 additional students. Sustained enrollment momentum, successful campus openings, and a recovery in margins once growth spending normalizes could support a higher valuation and, over time, a move toward the $38 area. From what I see, these enrollment trends remain worth monitoring closely.
The most immediate obstacle is the earnings outlook. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell 19.3% to $102 million as roughly $34.6 million of strategic growth spending weighed on results, and 2027 EPS guidance near zero signals limited near-term profitability. Execution risk in new-campus expansion, competitive pressure in for-profit education, and sensitivity to interest rates and student-financing regulation could further compress the multiple. A Hold-rated downgrade already highlights that some analysts see near-term headwinds outweighing the long-term growth story.
The stock has carved out a lower range after the mid-2026 decline. The $18–$20 zone, near the 52-week low, is a key support area, while the $30s represent a broad resistance band where the stock stalled earlier. The $51 peak from mid-2026 marks the upper end of the long-term range. A sustained push toward $38 would require the shares to clear resistance near $30 first, with the psychological $25 level as an intermediate hurdle.
Analyst price targets generally reflect a roughly 12-month horizon, though the timing and assumptions vary by firm. Investors should watch the next quarterly report for confirmation of enrollment trends and whether EPS guidance is revised, along with any analyst target changes following the latest guidance. Broader factors — interest-rate decisions by the FOMC (Federal Open Market Committee), student-financing and regulatory developments, and sector sentiment toward for-profit education — will also matter. I'm watching this closely for any shifts in guidance.
In my own research process, I find that AI Daily Buy/Sell Signals provide a practical way to stay on top of price action and trend shifts without constant manual review. These signals draw on artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold alerts based on technical behavior and market conditions. For a name like UTI, where enrollment data and guidance revisions can move the stock quickly, this kind of tool helps highlight when momentum may be changing. It serves as a useful complement to fundamental work rather than a replacement for it.
The $38 target for UTI is the average of six analyst price targets, not a guaranteed outcome, and it sits roughly 70% above recent prices — a very large required move. The company's revenue growth and enrollment momentum are real supports, but a sharp cut to fiscal 2027 earnings guidance, margin compression from growth spending, and a wide analyst range of roughly $30 to $45 (with one Hold at $25) underscore meaningful disagreement and risk. Whether UTI can reach $38 will depend chiefly on whether enrollment and campus expansion translate back into profit growth, and whether analysts maintain or raise their targets as new results arrive. Investors should monitor earnings, guidance revisions, and analyst updates rather than treat any single price level as certain.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where UTI declined for three days, in 196 of 262 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
The 10-day RSI Indicator for UTI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 28 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 68 cases where UTI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
The Momentum Indicator moved above the 0 level on November 16, 2026. You may want to consider a long position or call options on UTI as a result. In 74 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for UTI just turned positive on November 10, 2026. Looking at past instances where UTI's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
UTI moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for UTI crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +16.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 259 of 330 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 185 of 250 cases where UTI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. UTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.189) is slightly higher than the industry average of (1.158). UTI has a moderately high P/E Ratio (32.145) as compared to the industry average of (8.484). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.151) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties